Lirilumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | KIR2DL1/2/3 |
| Identifiers | |
| CAS Number | 1000676-41-4 |
| ATC code | none |
| Chemical data | |
| Formula | C6452H9918N1698O2030S46 |
| Molecular mass | 145.2 kg/mol |
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.<Romagné et al., Blood 2009 http://bloodjournal.hematologylibrary.org/content/114/13/2667.full.pdf>
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Bristol-Myers Squibb
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
